• Mashup Score: 4
    Wolters Kluwer Health - 10 month(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of NeurologyToday
      NeurologyToday

      Via @JAMANeuro: #Ocrelizumab seems to be more effective than dimethyl fumarate or fingolimod for keeping relapsing-remitting #MultipleSclerosis in check when switching from natalizumab: https://t.co/Rut5GNXOP5 #neurotwitter #MS @AANMember https://t.co/11RnA8cTL7

  • Mashup Score: 0
    Ocrelizumab for multiple sclerosis - Lin, M - 2022 | Cochrane Library - 2 year(s) ago

    Collapse all Expand all Background Ocrelizumab is a humanised anti‐CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing‐remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Ocrelizumab is the only…

    Source: www.cochranelibrary.com
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of WileyHealth
      WileyHealth

      What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This @CochraneLibrary #SystematicReview evaluates the evidence from 4 studies with 2551 people with #MS. >> https://t.co/uCu1xwJNlC https://t.co/bebMdo9ZlL

  • Mashup Score: 0
    Ocrelizumab for multiple sclerosis - Lin, M - 2022 | Cochrane Library - 2 year(s) ago

    Collapse all Expand all Background Ocrelizumab is a humanised anti‐CD20 monoclonal antibody developed for the treatment of multiple sclerosis (MS). It was approved by the Food and Drug Administration (FDA) in March 2017 for using in adults with relapsing‐remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). Ocrelizumab is the only…

    Source: www.cochranelibrary.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CochraneLibrary
      CochraneLibrary

      💊 What are the benefits and risks of #ocrelizumab for #MultipleSclerosis? This #systematicreview evaluates the evidence from 4 studies w 2551 people with #MS 📃 https://t.co/8DQFsKlf5f https://t.co/483sD1gBr8

  • Mashup Score: 0
    B-cell therapies, mycophenolate worsen COVID-19 vaccine response in inflammatory disease - 2 year(s) ago

    Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.“It is well established that patients with various autoimmune diseases who are on immunosuppression are at increased risk for severe manifestations of

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      “B-cell depleting agents, such as #rituximab or #ocrelizumab, had profound impacts on antibody production,” said Dr Alfred H. J. Kim @WUSTL “The next group that had the most impactful reduction in antibody titers was #mycophenolate ...” #ACR21 https://t.co/A1s4lZZhZG

  • Mashup Score: 11
    Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis - 3 year(s) ago

    Background and Objectives To report safety of ocrelizumab (OCR) up to 7 years in patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) enrolled in clinical trials or treated in real-world postmarketing settings. Methods Safety analyses are based on integrated clinical and laboratory data for all patients who received OCR in 11 clinical trials,…

    Source: Neurology
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of GreenJournal
      GreenJournal

      Safety of #Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis: https://t.co/yxV1qmPwwE #MS #Neurology https://t.co/FCthlrAjbG

  • Mashup Score: 1
    Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19 - 3 year(s) ago

    Objective To evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic. Methods In our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at…

    Source: Neurology Neuroimmunology & Neuroinflammation
    Categories: Latest Headlines, Neurology
    Tweet Tweets with this article
    • Profile photo of GreenJournal
      GreenJournal

      What are the clinical consequences of extended interval dosing (EID) of #ocrelizumab in relapsing-remitting multiple #sclerosis (RRMS) during the #COVID-19 pandemic? Read the study now: https://t.co/yJoeysKE1g #neurology https://t.co/U8Xr9JHkc6

Load More